SciClone Pharmaceuticals (Holdings) (HKSE:06600) Short-Term Debt : HK$0 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is SciClone Pharmaceuticals (Holdings) Short-Term Debt?

SciClone Pharmaceuticals (Holdings)'s Short-Term Debt for the quarter that ended in Dec. 2023 was HK$0 Mil.

SciClone Pharmaceuticals (Holdings)'s quarterly Short-Term Debt increased from Dec. 2022 (HK$467 Mil) to Jun. 2023 (HK$474 Mil) but then declined from Jun. 2023 (HK$474 Mil) to Dec. 2023 (HK$0 Mil).

SciClone Pharmaceuticals (Holdings)'s annual Short-Term Debt declined from Dec. 2021 (HK$468 Mil) to Dec. 2022 (HK$467 Mil) and declined from Dec. 2022 (HK$467 Mil) to Dec. 2023 (HK$0 Mil).

SciClone Pharmaceuticals (Holdings) Short-Term Debt Historical Data

The historical data trend for SciClone Pharmaceuticals (Holdings)'s Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SciClone Pharmaceuticals (Holdings) Short-Term Debt Chart

SciClone Pharmaceuticals (Holdings) Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

Get a 7-Day Free Trial

928.18

468.41

466.65

SciClone Pharmaceuticals (Holdings) Semi-Annual Data
	Dec17	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Short-Term Debt	Get a 7-Day Free Trial						468.41	472.03	466.65	474.21	-

SciClone Pharmaceuticals (Holdings) Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

SciClone Pharmaceuticals (Holdings) Short-Term Debt Related Terms

Thank you for viewing the detailed overview of SciClone Pharmaceuticals (Holdings)'s Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

SciClone Pharmaceuticals (Holdings) (HKSE:06600) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SciClone Pharmaceuticals (Holdings) Ltd (HKSE:06600) » Definitions » Short-Term Debt

Traded in Other Exchanges

N/A

Address

381 Middle Huaihai Road, 22nd Floor, Central Plaza, Shanghai, CHN

Website

https://www.sciclone.com

SciClone Pharmaceuticals (Holdings) Ltd is a biopharmaceutical company with an integrated platform for product development and commercialization. It strategically focuses on some of the fast-growing therapeutic areas with unmet medical needs in China, primarily including oncology and severe infection. It generated revenue primarily from the sale of Zadaxin to Sinopharm.

Executives

Ubs Group Ag	2201 Interest of corporation controlled by you
Zhao Hong	2101 Beneficial owner
Gl Capital Management Gp Limited
Meng Liang	2201 Interest of corporation controlled by you
Ascendent Silver (cayman) Limited	2501 Other
Ascendent Capital Partners Ii Gp Limited	2201 Interest of corporation controlled by you
Ascendent Capital Partners Ii, Gp, L.p.	2201 Interest of corporation controlled by you
Ascendent Capital Partners Ii, L.p.	2201 Interest of corporation controlled by you
Gl Partners Capital Management Ltd.
Gl China Opportunities Carry Gp Limited
Ocean Falcon Limited	2101 Beneficial owner
Central Huijin Investment Ltd.	2201 Interest of corporation controlled by you
Bank Of China Limited	2201 Interest of corporation controlled by you
Bank Of China Group Investment Limited	2201 Interest of corporation controlled by you
Gl Capital Management Gp Ii B.c I. Ltd

SciClone Pharmaceuticals (Holdings) (HKSE:06600) Headlines

No Headlines